Shots:
- J&J has reported P-IIIb (APEX) trial data assessing Tremfya vs PBO in biologic-naïve PsA pts with inadequate response to standard therapies for 24wks., followed by a 12wk. safety follow-up; eligible pts could enter a 2yr. extension phase prior to the final safety follow-up
- Trial met its 1EP of improved ACR20 response, showing reduced signs & symptoms as well as its 2EP of less structural damage progression per PsA-modified vdH-S score, incl. joint space narrowing & erosion at 24wks.; data to be highlighted in future conferences
- APEX trial will continue to evaluate the sustained efficacy of Tremfya in inhibiting structural damage in pts with active PsA
Ref: J&J | Image: J&J
Related News:- J&J MedTech Reports the US FDA‘s 510(k) Clearance of MONARCH QUEST for Robot-Assisted Bronchoscopy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
